Australian Advantage

Why choose Australia & Crux Biolabs for your clinical studies?

Bespoke, reliable, timely & cost-effective contract immunology services. At Crux Biolabs, we take pride in becoming an extension of your team. We are 100% Australian-owned and located in Melbourne, the biotech capital of Australia.

The Australian
Advantage

  • The Australian Regulatory Framework: CTN scheme 4-8 weeks for review, less than 12 weeks for study start-up
  • No requirement for IND
  • Melbourne, Victoria is a recognized leader in early-stage clinical trials, known for the quality of its clinical sites and the clinician expertise that facilitates the timely execution of excellent clinical trials
  • Data generated at Crux Biolabs is ICH, FDA and EMA compliant and accepted for Phase 2 & 3 studies conducted globally
  • Crux Biolabs is a registered Research Service Provider with the Australian Government. This allows easy claims for the full R&D Tax Incentive: 43.5% cash back for every $1 spent in R&D in Australia, available to international and local sponsors
Quality Standards

Quality Standards

Crux Biolabs offers services to the highest industry standards with a strong quality focus. Our team takes pride in the quality and consistency of the tests and data generated on behalf of our sponsors and clients.

  • NATA Accreditation
  • Validated ISO 17025 assays
  • International QAP programs for PBMC Processing, ELISpot, ELISA and FluroSpot, Luminex
  • Tailored assay development and qualification or validation according to international regulatory ICH, FDA and EMA guidelines, industry standards, and project specific requirements
  • Through the combined expertise of our scientific team we offer a broad portfolio of immunology, biomarker and cellular testing services